Collapse all
The Business Model Canvas reveals a high-value precision medicine play that shifts the cost burden from chronic medication to acute intervention. Success depends on integrating with clinical workflows and securing insurance reimbursement by proving a reduction in long-term functional disability costs.
4 Clinical Research Organizations (CROs) Partners to provide longitudinal patient data to refine the predictive algorithm for psilocybin response. Psychiatric Clinics Early adopters who provide the real-world clinical environment for tool validation and user feedback. FDA/Regulatory Bodies Essential for certifying the tool as a Software as a Medical Device (SaMD) for clinical decision support. Pharmaceutical Manufacturers Companies producing synthetic psilocybin who benefit from targeted patient selection to increase trial success rates. 4 Predictive Model Development Analyzing treatment-resistance history and symptom severity to build a high-accuracy classification engine. Clinical Validation Running comparative studies to prove the tool correctly identifies psilocybin responders over SSRI responders. UI/UX Integration Designing a seamless interface that fits into the psychiatrist's existing patient intake and diagnostic workflow. Health Economic Modeling Quantifying the cost-savings of single-dose interventions versus lifelong daily SSRI prescriptions for insurers. 3 Proprietary Patient Datasets Aggregated data on MDD treatment trajectories, specifically comparing escitalopram and psilocybin outcomes. Bioinformatics/ML Talent Specialists capable of building a robust diagnostic tool that avoids overfitting in small clinical cohorts. Clinical IP Patents or trade secrets surrounding the specific biomarkers or profile markers used for prediction. 3 For Psychiatrists: Precision Prescribing Reduces trial-and-error prescribing by identifying patients who need rapid functional recovery versus those suited for gradual SSRI onset. For Insurers: Cost Reduction Lowers long-term pharmacy spend and disability claims by shifting eligible patients to a single-dose curative model. For Patients: Optimized Recovery Faster reduction in functional disability for those with treatment-resistant depression who would otherwise fail multiple SSRIs. 3 B2B Clinical Partnership High-touch relationship with clinic leads to ensure the tool is integrated into standard operating procedures. Evidence-Based Trust Maintaining credibility through the publication of peer-reviewed validation studies in psychiatric journals. Enterprise Account Management Working with insurance payers to establish reimbursement codes for the use of the screening tool. 3 Electronic Health Record (EHR) Integration Direct API integration into platforms like Epic or Cerner where psychiatrists manage patient profiles. Medical Conferences Presenting at psychiatry and precision medicine summits to reach key opinion leaders (KOLs). Direct B2B Sales Targeting large healthcare networks and insurance provider groups. 3 Psychiatrists Clinicians treating moderate-to-severe MDD, particularly those specializing in treatment-resistant depression. Health Insurance Companies Payers seeking to reduce the long-term cost of chronic mental health medication and associated disability. Specialized Psychedelic Clinics New-age clinics focusing on rapid-intervention therapies who need a rigorous screening process for safety and efficacy. 3 R&D and Data Acquisition High initial costs for acquiring clinical trial data and developing the predictive algorithm. Regulatory Compliance Costs associated with FDA clearance and maintaining HIPAA-compliant data infrastructure. Software Maintenance Ongoing costs for cloud hosting and integrating with various EHR systems. 3 Per-Screening Fee A fee paid by the clinic or insurer for every patient screened using the tool. Annual SaaS Subscription Recurring license fee for clinics to have unlimited access to the decision-support software. Data Licensing Anonymized aggregate data insights sold to pharmaceutical companies developing new rapid-acting antidepressants. The tool has clearly defined beneficiaries (psychiatrists and insurers), making it necessary to map how value is captured and delivered. · Generated 2026-09-05 by cavi/gemma4-31b-it-awq-4bit-32kAI-generated